597 related articles for article (PubMed ID: 24813579)
1. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
2. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
3. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
4. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
Feldmeyer L; Hofbauer GF; Böni T; French LE; Hafner J
Br J Dermatol; 2012 Feb; 166(2):422-4. PubMed ID: 21895616
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Barysch MJ
Praxis (Bern 1994); 2016 Sep; 105(18):1071-7. PubMed ID: 27606914
[No Abstract] [Full Text] [Related]
8. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010.
Mudigonda T; Levender MM; O'Neill JL; West CE; Pearce DJ; Feldman SR
Dermatol Surg; 2013 Mar; 39(3 Pt 1):345-64. PubMed ID: 23190408
[TBL] [Abstract][Full Text] [Related]
9. Overview on non-melanoma skin cancers in solid organ transplant recipients.
Forchetti G; Suppa M; Del Marmol V
G Ital Dermatol Venereol; 2014 Aug; 149(4):383-7. PubMed ID: 25068224
[TBL] [Abstract][Full Text] [Related]
10. Skin cancer in liver transplant recipients.
Otley CC; Pittelkow MR
Liver Transpl; 2000 May; 6(3):253-62. PubMed ID: 10827224
[TBL] [Abstract][Full Text] [Related]
11. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.
Ulrich C; Jürgensen JS; Degen A; Hackethal M; Ulrich M; Patel MJ; Eberle J; Terhorst D; Sterry W; Stockfleth E
Br J Dermatol; 2009 Nov; 161 Suppl 3():78-84. PubMed ID: 19775361
[TBL] [Abstract][Full Text] [Related]
12. Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer.
Karia PS; Azzi JR; Heher EC; Hills VM; Schmults CD
JAMA Dermatol; 2016 May; 152(5):533-40. PubMed ID: 26792250
[TBL] [Abstract][Full Text] [Related]
13. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
16. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of non-melanocytic skin tumors].
Hafner J
Ther Umsch; 1998 Aug; 55(8):515-21. PubMed ID: 9757819
[TBL] [Abstract][Full Text] [Related]
18. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Dantal J; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; Del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra A; Hofbauer GFL; Kamar N; Pouteil-Noble C; Kanitakis J; Roux A; Decullier E; Euvrard S;
J Clin Oncol; 2018 Sep; 36(25):2612-2620. PubMed ID: 30016177
[TBL] [Abstract][Full Text] [Related]
20. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]